Company & Sponsor Intelligence
Eli Lilly and Company
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials5
Recruiting1
Completed4
Countries2
Therapeutic footprint
adhdalzheimers
Indexed studies
NCT00191880Open-Label Trial of Atomoxetine to Evaluate Academic Outcome in Children Ages 8-11 Years With Attention Deficit/Hyperactivity Disorder
adhd · CanadaPHASE3
adhd · CanadaPHASE3
NCT00510146Olanzapine Treatment of Patients With Bipolar I Disorder
depression · ChinaPHASE3
depression · ChinaPHASE3
NCT05026866A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
alzheimers · United StatesPHASE3
alzheimers · United StatesPHASE3
NCT01837641A Study of LY3002813 in Participants With Alzheimer's Disease
alzheimers · United StatesPHASE1
alzheimers · United StatesPHASE1
NCT00485875Safety and Efficacy of Switching From a Stimulant Medication to Atomoxetine in Children and Adolescents With ADHD
adhd · United StatesPHASE4
adhd · United StatesPHASE4
NCT03367403A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)
alzheimers · United StatesPHASE2
alzheimers · United StatesPHASE2
Intelligence layer updated: 2026-06-10 02:57:56.223123+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →